期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

肿瘤的基因靶向检测和治疗 被引量：1

Gene targeting diagnosis and treatment in cancer
原文传递
导出
摘要 随着分子靶向药物和个体化治疗的研发和临床使用，肿瘤的基因靶向检测和治疗已成为肿瘤治疗的热点。尤其是针对表皮生长因子受体（EGFR）信号通路相关基因、DNA复制相关基因、纺锤体形成相关基因、细胞代谢过程相关基因等分子靶向检测和治疗，靶点分子的基因多态性决定了靶向药物治疗的有效性。 With the development and clinical use of the molecular targeted drugs and individualized treatment, cancer research has been focused on gene targeting diagnosis and treatment. Especially for the epidermal growth factor receptor （EGFR） signaling pathway-related genes, DNA replication-related genes, spindle apparatus format-related genes, cell metabolism-related genes and other molecular targeted detection and treatment, the polymorphism of targeting genes/molecules determines the clinical efficiency of the therapies.
作者 郑亚冰 王林 常晓天
机构地区 山东省医学科学院生物技术研究中心
出处 《国际肿瘤学杂志》 CAS 2012年第3期186-189,共4页 Journal of International Oncology
关键词 肿瘤 分子诊断技术 抗肿瘤药 Neoplasms Molecular diagnostic techniques Antineoplastic agents
分类号 R730.5 [医药卫生—肿瘤]
  • 相关文献

参考文献15

  • 1Wynn ML, Ventura AC, Sepulchre JA, et al. Kinase inhibitors canproduce off-target effects and activate linked pathways by retroactivity. BMC Syst Biol, 2011,5(1) :156.
  • 2Han W, Pan H, Chen Y, et al. EGFR tyrosine kinase inhibitors activate autophagy as a cytoprotective response in human lung cancer cells. PLoS One, 2011,6(6) :e18691.
  • 3Yoshida T, Zhang G, Haura EB. Targeting epidermal growth factor receptor: central signaling kinase in lung cancer. Biochem Pharmacol. 2010.80(5):613-623.
  • 4朱明训(综述),陈建荣(审校),蔡映云(审校).表皮生长因子在肺癌治疗中的应用[J].国际肿瘤学杂志,2009,36(11):853-855. 被引量：1
  • 5Scahriti M, Rojo F, Ocana A, et al. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst, 2007, 99 (8) :628-638.
  • 6陈慧娟,李洪波,李硕敏,鲁碧稳,程俊峰,刘元力.k-ras基因突变与结直肠癌的关系[J].肿瘤研究与临床,2010,22(7):461-463. 被引量：8
  • 7Zhang J, Roberts TM, Shivdasani RA. Targeting PI3K signaling as a therapeutic approach for colorectal cancer. Gastroenterology, 2011, 141 ( 1 ) :50-61.
  • 8Tzvetkov MV, Behrens G, O'Brien VP, et al. Pharmacogenetic analyses of cisplatin-induced nephrotoxicity indicate a renoprotective effect of ERCC1 polymorphisms. Pharmacogenomics, 2011, 12(10) : 1417-1427.
  • 9Nitiss JL. Targeting DNA topoisomerase II in cancer chemotherapy. Nat Rev Cancer, 2009, 9(5) :338-350.
  • 10Boukovinas I, Papadaki C, Mendez P, et al. Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients. PLoS One, 2008, 3 ( 11 ) : e3695.

二级参考文献63

  • 1Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics 2002. CA Cancer J Clin, 2005. 55 (2) :74-108.
  • 2Hodkinson PS. Mackinnon A. Sethi T. et al. Targeting growth factors in lung cancer. Chest, 2008. 133 ( 5 ) : 1209-1216.
  • 3Tiseo M, Loprevite M, Ardizzoni A, et al. Epidermal growth factor receptor inhibtors: a new prospective in the treatment of lung cancer. Curt Med Chem Anticancer Agents. 2004, 4 ( 2 ) : 139-148.
  • 4Lemos-Gonzalez Y. Rodriguez-Berrocal FJ, Cordero OJ. et al. Alteration of the serum levels of the epidermal growth factor receptor and its ligands in patients with non-small cell lung cancer and head and neck varcinoma. Br J Cancer , 20(17, 96(10) : 1569-1578.
  • 5Shepherd FA, Pereira JR, Ciuleanu T, et at. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med, 2005, 353( 2 ): 123-132.
  • 6Bezjak A. Tu DS. Sewnour L, et al. Symplom improvement in tung cancer patients treated with erlotinib : quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR 21. J Cliu Oncol, 2006. 24(24):3831-3837.
  • 7Tbatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell hmg cancer: Results from a randomised, placebo-controlled. multicentre study ( lressa Survival Evaluation in Lung Cancer). Lancet, 200.5, 366 ( 9496 ) : 1527-1537.
  • 8West HL, Franklin WA, McCoy J, et al. Gefitinib therapy in advancedbronchioloalveolar carcinoma : Southwest Oncology Group Study S0126. J Clin Oncol, 2006. 24(12) :1807-1813.
  • 9Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non- small-cell lung cancer to gefitinib. N Engl J Med, 2004, 350(21 ) : 2129-2139.
  • 10Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science, 2004, 304(.5676) :1497-1500.

共引文献10

同被引文献4

引证文献1

国际肿瘤学杂志
2012年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部